Stock Markets April 16, 2026 03:26 PM

OpenAI Debuts GPT-Rosalind to Support Life Sciences Research

New research-preview model aims to assist biochemical and drug-discovery workflows through evidence synthesis and experimental planning

By Leila Farooq AMGN
OpenAI Debuts GPT-Rosalind to Support Life Sciences Research
AMGN

OpenAI has unveiled GPT-Rosalind, an AI model tailored to life sciences research. Positioned to assist tasks from literature review to experimental suggestion, the model is being offered as a research preview through ChatGPT, Codex and the API for eligible customers and accompanied by a free Codex plugin connecting users to over 50 scientific tools and data sources. OpenAI said it is collaborating with companies including Amgen, Moderna and Thermo Fisher Scientific to deploy the model in research workflows.

Key Points

  • OpenAI introduced GPT-Rosalind, an AI model focused on biochemistry, drug discovery and translational medicine, intended to support early-stage research tasks.
  • The model is offered as a research preview in ChatGPT, Codex and via API for qualified customers, and includes a free Codex plugin connecting users to over 50 scientific tools and data sources.
  • OpenAI said it is collaborating with companies including Amgen, Moderna and Thermo Fisher Scientific to integrate GPT-Rosalind into research workflows - sectors impacted include pharmaceuticals, biotech and academic research.

OpenAI introduced GPT-Rosalind on Thursday, a purpose-built artificial intelligence model that the company says increases biology knowledge and supports scientific research activities. Named after the 20th-century British scientist Rosalind Franklin, the model is aimed at researchers working in biochemistry, drug discovery and translational medicine.

OpenAI describes GPT-Rosalind as a tool to support multi-step research tasks such as evidence synthesis, hypothesis generation and experimental planning. In a blog post, the company said the model is designed to help researchers accelerate the early stages of discovery by assisting with those foundational activities.

According to materials presented in a press briefing, researchers will be able to use GPT-Rosalind to interrogate databases, read and interpret recent scientific papers, operate other scientific tools and propose new experiments. The model was developed using OpenAI's newest internal models as a base, the company said.

OpenAI is making GPT-Rosalind available as a research preview inside ChatGPT, in Codex and through the API for qualified customers, using what it describes as a trusted access deployment structure. In parallel, the company said it is launching a free Life Sciences research plugin for Codex that connects scientists to more than 50 scientific tools and data sources.

The company stated it is working with a set of customers, naming Amgen, Moderna and Thermo Fisher Scientific among organizations that will apply GPT-Rosalind across their research workflows. OpenAI emphasized the model's role in facilitating early-stage research activities rather than offering definitive scientific conclusions.

The announcement of GPT-Rosalind follows recent product activity from the company, including the unveiling on Tuesday of GPT-5.4-Cyber, a variant of its newest flagship model that has been fine-tuned for defensive cybersecurity work. The release came in close timing to announcements from other firms developing frontier AI models.


While the new model and supporting tools are aimed at accelerating research, OpenAI framed GPT-Rosalind primarily as a research-oriented capability currently available to qualified users as a preview. The company positioned the launch as part of a broader push to deepen its footprint in life sciences research and to connect computational tools and data sources for scientific workflows.

Risks

  • GPT-Rosalind is currently available as a research preview and access is limited to qualified customers through a trusted access deployment structure, which may constrain broad adoption in the near term.
  • The model is positioned to assist with early-stage research tasks such as hypothesis generation and experimental planning, rather than delivering definitive scientific results, indicating uncertainty around direct research outcomes.
  • OpenAI is working with selected partners to apply the model across workflows, but the scope and scale of those applications beyond named customers were not detailed, leaving questions about wider industry deployment.

More from Stock Markets

Kone Advances Talks to Buy TK Elevator in Potentially Major European Deal Apr 16, 2026 FAA to Limit Daily Flights at Chicago O’Hare This Summer to Prevent Worsening Delays Apr 16, 2026 Soaring Fuel Costs Threaten Spirit Airlines' Exit from Bankruptcy and Raise Liquidation Concerns Apr 16, 2026 After-Hours Movers: Netflix Guidance, Alcoa Miss, Knight-Swift Cut, Trevi Offering, NiSource Deal Lift Apr 16, 2026 NiSource Gains After Deals to Power Large Indiana Data Centers for Alphabet and Amazon Apr 16, 2026